CBD-oriented epilepsy launched by the GW Pharma

GW Pharma has been cleared to market the first plant-derived cannabis-based medicine in Europe to treat epilepsy conditions, CEO Justin Gover told CNBC’s Jim Cramer Tuesday. European Union officials this week approved the use of Epidyolex to treat seizures in patients with two rare, severe forms of childhood-onset epilepsy and GW Pharma executives are optimistic about its prospects across the pond. “We have 28 countries now in Europe th....